Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a community health worker program save lives in advanced HIV?

NCT ID NCT07720128

Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This trial tests whether a package of support from a community health worker can help adults hospitalized with advanced HIV in Lusaka, Zambia, stay in care and survive longer. Participants are randomly assigned to receive the ARC intervention or standard care and are followed for up to one year after discharge. The study measures mortality, viral suppression, and retention in HIV care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A multi-component support package delivered by a community health worker, including medical and psychosocial help for advanced HIV disease and hospitalization
What this could lead to
If effective, this approach could reduce deaths and improve viral suppression among people with advanced HIV who are hospitalized.
What could go wrong
This is a single-site trial in Lusaka, Zambia, so results may not apply elsewhere. The intervention is complex and resource-intensive, and its success depends on community health worker availability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 724 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2027

An estimate. Start dates often move.

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Living with HIV * Advanced HIV defined as CD4 \<350 cells/mm3 or WHO stage 3 or 4 event * Currently admitted to study hospital's internal medicine department Exclusion Criteria: * Planning to reside outside Lusaka after discharge * Too sick to provide informed consent * Known to have advanced cancer (defined as requiring chemo/radiation therapy or referred to hospice) other than Kaposi Sarcoma * Known to have end stage kidney disease * Known to have end stage liver disease * No access to a telephone * Currently incarcerated

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced HIV disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced HIV disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Teaching Hospital

    Lusaka, Zambia

More trials for these conditions

Other studies related to the condition(s) this trial covers.